ReviewDiagnostics (Basel, Switzerland)2023
Update on the Role of FeNO in Asthma Management.
Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Fractional Exhaled Nitric Oxide Testing for the Diagnosis and Management of Asthma: a Health Technology Assessment.Ontario health technology assessment series · 2024Pooled it
- The Efficacy of Daily Salmon Oil for Adult Type 2 Asthma: An Exploratory Randomized Double-Blind Trial.Marine drugs · 2025Trial
- Small airway dysfunction as a functional barrier to spirometry-defined clinical remission in severe asthma treated with biologic therapies.The World Allergy Organization journal · 2026Article
- Therapeutic Switching of Biological Drugs in Paediatric Severe Asthma: Experience of a Referral Centre.Biomedicines · 2026Article
- Short-term longitudinal variation in exhaled nitric oxide fraction predicts future moderate-to-severe exacerbations in COPD patients on triple therapy: a prospective cohort study.ERJ open research · 2026Article
- Reframing paucigranulocytic asthma through genetic endotyping: a hypothesis-generating focus on the 17q21 rs7216389 locus.Current opinion in allergy and clinical immunology · 2026Review
- The silent zone of paediatric asthma: integrating small airway dysfunction assessment into clinical practice.EClinicalMedicine · 2026Review
- Distal Airway Inflammation Is Linked to Small Airway Dysfunction in Asthma.Medical sciences (Basel, Switzerland) · 2026Observational
- HAntioxidants (Basel, Switzerland) · 2026Article
- Respiratory Biomarkers: An Opportunity for Patient-Centric Microsampling Approach for Treatment Optimization.Clinical and translational science · 2026Review
- Inhaled Corticosteroid/Long-Acting βAdvances in therapy · 2026Review
- IL-33 associates with type 2 burden and lung function in paediatric asthma, alongside exploratory IL-33-linked lipid changes.BMC pediatrics · 2026Article
- Impact of systemic steroids on asthma biomarkers: A comprehensive analysis.The World Allergy Organization journal · 2026Review
- A Room-Temperature, High-ppb-Level NO Gas Sensor Based on Pt/WOSensors (Basel, Switzerland) · 2026Article
- CURE: a phase-based therapeutic framework for chronic inflammation.Frontiers in immunology · 2026Review
- Short-term efficacy of nebulized budesonide for allergic airway inflammation in young children and dynamic changes in fractional exhaled nitric oxide (FeNO): a retrospective cohort study.American journal of translational research · 2026Article
- Development and internal validation of a multidimensional nomogram integrating PIV, LDH, and FeNO for predicting poor asthma control in school-aged children.Frontiers in pediatrics · 2026Article
- Integrated pro-resolving mechanisms: a new dimension for optimizing anti-inflammatory therapy in asthma - a review of impaired inflammation resolution in airway remodeling.Frontiers in immunology · 2026Review
- Advancements in diagnosis, preventive care, and future directions in the holistic management of pediatric asthma.Frontiers in pediatrics · 2026Review
- Exploring associations between nasal fluid inflammatory proteins and patient-reported symptom burden in respiratory disease.Frontiers in allergy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a heterogenous disorder characterized by presence of different phenotypes and endotypes. Up to 10% of the individuals suffer from severe asthma and are at increased risk of morbidity and mortality. Fractional exhaled nitric oxide (FeNO) is a cost-effective, point of care biomarker that is used to detect type 2 airway inflammation. Guidelines have proposed to measure FeNO as an adjunct to diagnostic evaluation in individuals with suspected asthma and to monitor airway inflammation. FeNO has lower sensitivity, suggesting that it may not be a good biomarker to rule out asthma. FeNO may also be used to predict response to inhaled corticosteroids, predict adherence and deciding on biologic therapy. Higher levels of FeNO have been associated with lower lung function and increased risk for future asthma exacerbations and its predictive value increases when combined with other standard measurements of asthma assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.